Accessed: 10.03.2019
mhGAP Training Manual for the mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings – version 2.0 (for field testing)
Position Statement
Diabetes Care2018;42(Suppl. 1):S1–S194.
The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I...nterventions (WHO PEN) for primary care in low-resources settings, reviewing several newer oral agents as second- and third-line treatment: dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter 2 inhibitors and thiazolidinediones. The guidelines also present recommendations on the selection of type of insulin (analogue versus human insulin) for adults with type 1 and type 2 diabetes.
more
В этом дискуссионном документе излагаются факты, касающиеся передозировки опиоидов, мер, которые могут быть приняты в целях предупреждения и лечения (коррекции) п...редозировки опиоидов, и указываются области, требующие дальнейшего исследования.
more
Update of the Mental Health Gap Action Programme
(mhGAP) Guideline for Mental, Neurological and Substance use Disorders May 2015
Externalising disorders
Chapter D.2
Externalising disorders
Chapter D.3
Mood disorders
Chapter E.1
2015 edition
Mood disorders
Chapter E.2
Mood disorders
Chapter E.3
2016 edition
Mood disorders
Chapter E.4
2018 edition
Anxiety disorders
Chapter F.2
Anxiety disorders
Chapter F.3
Substance use disorders
Chapter G.3
Other disorders Chapter H.1
Other disorders
Chapter H.5
Other
Chapter H.4
2015 edition
Other disorders
Chapter H.5.1